Thomas Prebet

Thomas Prebet

UNVERIFIED PROFILE

Are you Thomas Prebet?   Register this Author

Register author
Thomas Prebet

Thomas Prebet

Publications by authors named "Thomas Prebet"

Are you Thomas Prebet?   Register this Author

100Publications

3674Reads

10Profile Views

Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.

Leuk Res 2020 Apr 26;91:106339. Epub 2020 Feb 26.

Smilow Cancer Center at Yale New Haven Hospital, 35 Park Street, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2020.106339DOI Listing
April 2020

Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease.

J Cutan Pathol 2019 Dec 26;46(12):930-934. Epub 2019 Aug 26.

Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13537DOI Listing
December 2019

Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.

Leuk Lymphoma 2019 Dec 9:1-16. Epub 2019 Dec 9.

Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1697812DOI Listing
December 2019

Insights into novel emerging epigenetic drugs in myeloid malignancies.

Ther Adv Hematol 2019 6;10:2040620719866081. Epub 2019 Aug 6.

Division of Hematology/Oncology, Smilow Cancer Center at Yale New Haven Hospital, 35 Park Street, New Haven, CT 06511, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620719866081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685116PMC
August 2019

What are the most promising new agents in myelodysplastic syndromes?

Curr Opin Hematol 2019 03;26(2):77-87

Smilow Cancer Center at Yale New Haven Hospital, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000483DOI Listing
March 2019

Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.

Leuk Lymphoma 2018 03 25;59(3):755-757. Epub 2017 Jul 25.

b Deptartment of Internal Medicine, Section of Hematology , Yale University School of Medicine , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1354373DOI Listing
March 2018

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.

Leuk Lymphoma 2017 08 2;58(8):1880-1886. Epub 2016 Dec 2.

h Service d'Hématologie , Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1263843DOI Listing
August 2017

Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.

Expert Opin Pharmacother 2017 Aug 1;18(12):1213-1224. Epub 2017 Aug 1.

a Section of Hematology, Department of Internal Medicine , Yale School of Medicine , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1349100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121132PMC
August 2017

Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.

Leuk Lymphoma 2017 05 21;58(5):1022-1036. Epub 2016 Sep 21.

a Department of Medicine (Hematology) , Yale School of Medicine , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1228927DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785935PMC
May 2017

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.

Leuk Lymphoma 2017 04 25;58(4):982-985. Epub 2016 Aug 25.

b Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center , Yale University , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1214954DOI Listing
April 2017

New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.

Expert Rev Hematol 2016 15;9(4):377-88. Epub 2016 Feb 15.

d Division of Hematology, Department of Medicine , Yale University , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2016.1135047DOI Listing
December 2016

Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.

Br J Haematol 2016 Dec 21;175(5):829-840. Epub 2016 Sep 21.

Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14305DOI Listing
December 2016

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.

Oncotarget 2016 Dec;7(52):85937-85947

Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.13262DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349887PMC
December 2016

Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.

Ann Hematol 2016 Oct 29;95(11):1895-8. Epub 2016 Jul 29.

Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-016-2761-4
Publisher Site
http://dx.doi.org/10.1007/s00277-016-2761-4DOI Listing
October 2016

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.

Haematologica 2016 10;101(10):e427-e428

Groupe Francophone des myélodysplasies, Hopital Saint Louis, Paris, France Service Hematologie 2, Institut Paoli-Calmettes, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.150714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5046667PMC
October 2016

Epigenetics in Cancer: A Hematological Perspective.

PLoS Genet 2016 Oct 10;12(10):e1006193. Epub 2016 Oct 10.

Department of Internal Medicine, Section of Hematology, Yale Cancer Center at Yale University, New Haven, Connecticut, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pgen.1006193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065123PMC
October 2016

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.

Expert Opin Investig Drugs 2016 ;25(3):307-17

b Department of Internal Medicine, Section of Hematology , Yale University School of Medicine , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2016.1146251DOI Listing
September 2016

Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?

Blood Rev 2016 09 25;30(5):381-8. Epub 2016 Apr 25.

Section of Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0268960X163001
Publisher Site
http://dx.doi.org/10.1016/j.blre.2016.04.006DOI Listing
September 2016

Trends in Clinical Investigation for Myelodysplastic Syndromes.

Clin Lymphoma Myeloma Leuk 2016 08;16 Suppl:S57-63

Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.02.012DOI Listing
August 2016

Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients.

Cancer Res 2016 04 9;76(8):2082-6. Epub 2016 Mar 9.

Cancer Research UK, London Research Institute, The Francis Crick Institute, London, United Kingdom. Haematopoeitic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2063DOI Listing
April 2016

Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer.

PLoS One 2015 11;10(5):e0123768. Epub 2015 May 11.

CRCM, Team Cell Polarity, Cell signalling and Cancer "Equipe labellisée Ligue Contre le Cancer", Inserm, U1068, Marseille, F-13009, France; Institut Paoli-Calmettes, Marseille, F-13009, France; Aix-Marseille Université, Marseille, F-13284, France; CNRS, UMR7258, F-13009, Marseille, France; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123768PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427440PMC
February 2016

Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.

Am J Hematol 2015 Feb 19;90(2):E29-30. Epub 2014 Nov 19.

Hematology Department, Institut Paoli Calmettes, Marseille, France; Aix-Marseille University, Medecine Faculty, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23884DOI Listing
February 2015

Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.

Am J Hematol 2015 Jan 18;90(1):E22-4. Epub 2014 Oct 18.

Hematology Department, Institut Paoli Calmettes, Marseille, France; Aix-Marseille University, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23850DOI Listing
January 2015

Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.

Biol Blood Marrow Transplant 2014 Oct 14;20(10):1560-5. Epub 2014 Jun 14.

Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France; Aix-Marseille Université, Marseille, France; Inserm UMR 1068/Centre de Recherche en Cancérologie de Marseille, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.06.006DOI Listing
October 2014

Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.

Am J Hematol 2014 Jun 10;89(6):604-9. Epub 2014 Apr 10.

Centre de Recherche en Cancérologie de Marseille, Aix-Marseille University, Marseille, France; Laboratoire d'Oncologie Moléculaire, UMR1068 Inserm, CNRS UMR7258, Aix-Marseille University, Marseille, France; Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.23702
Publisher Site
http://dx.doi.org/10.1002/ajh.23702DOI Listing
June 2014

Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity.

Front Immunol 2014 24;5:122. Epub 2014 Mar 24.

Centre de Cancérologie de Marseille, INSERM, U1068, Institut Paoli-Calmettes, Aix-Marseille Université, UM 105, CNRS, UMR7258 , Marseille , France ; Centre de Cancérologie de Marseille, Plateforme d'Immunomonitoring en Cancérologie, INSERM, U1068, Institut Paoli-Calmettes, Aix-Marseille Université, UM 105, CNRS, UMR7258 , Marseille , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2014.00122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970020PMC
June 2014

Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?

Expert Rev Hematol 2014 Apr 24;7(2):191-4. Epub 2014 Feb 24.

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.891437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124601PMC
April 2014

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

J Clin Oncol 2014 Apr 24;32(12):1242-8. Epub 2014 Mar 24.

Thomas Prebet, James Herman, Lisa Malick, and Steven D. Gore, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Zhuoxin Sun, Dana-Farber Cancer Institute, Boston, MA; Maria E. Figueroa and Ari Melnick, Weill Cornell Medical College; Janice Gabrilove, Mount Sinai School of Medicine; Martin S. Tallman, Leukemia Service, Memorial Sloane-Kettering Cancer Center, New York; Elisabeth Paietta, North Division, Montefiore Medical Center, Bronx, NY; Rhett Ketterling and Mark Litzow, Mayo Clinic, Rochester, MN; Peter L. Greenberg, Stanford University Cancer Center, Stanford, CA; Mark Juckett, University of Wisconsin, Madison, WI; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Magdalena Czader, Indiana University Cancer Center, Indianapolis, IN; and Harry P. Erba, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.3102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986386PMC
April 2014

Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women's fertility.

Clin Lymphoma Myeloma Leuk 2013 Dec 24;13(6):704-10. Epub 2013 Sep 24.

Department of Oncology, Institut Paoli-Calmettes, Marseille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.05.014DOI Listing
December 2013

[Myelodysplastic syndromes].

Rev Prat 2013 Dec;63(10):1445-50

Université Aix-Marseille et institut Paoli-Calmettes, 232, bd Sainte-Marguerite, 13009 Marseille, France.

View Article

Download full-text PDF

Source
December 2013

Concomitant germ-line RUNX1 and acquired ASXL1 mutations in a T-cell acute lymphoblastic leukemia.

Eur J Haematol 2013 Sep 28;91(3):277-9. Epub 2013 Jun 28.

Faculté de Médecine, Aix-Marseille Université, Marseille, France; Département d'Hématologie, Institut Paoli-Calmettes, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12147DOI Listing
September 2013

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.

Haematologica 2013 Feb 14;98(2):e18-9. Epub 2012 Sep 14.

Department of Hematological Malignancies, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2012.071050DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561445PMC
February 2013

Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.

Genes Chromosomes Cancer 2012 Dec 30;51(12):1086-92. Epub 2012 Aug 30.

Laboratoire d'Hématologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP)/Université Paris 13, Bobigny. France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.21993DOI Listing
December 2012

Design of N-substituted amino caproic hydroxamic acid histone deacetylase inhibitors reveal an essential role for cap atomic composition.

Anticancer Agents Med Chem 2012 Sep;12(7):801-6

Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille-CRCM, Laboratory of Integrative Structural & Chemical Biology-iSCB, UMR CNRS 7258,Inserm-U1068, Faculté de Pharmacie, 27 Bd Jean Moulin, 13385 Marseille Cedex 05, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187152012802650192DOI Listing
September 2012

[Histone methyltransferases: a new class of therapeutic targets in cancer treatment?].

Med Sci (Paris) 2011 Aug-Sep;27(8-9):725-32. Epub 2011 Aug 31.

Centre de recherche en cancérologie de Marseille, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/2011278014DOI Listing
November 2011

PTK7: a cell polarity receptor with multiple facets.

Cell Cycle 2011 Apr 15;10(8):1233-6. Epub 2011 Apr 15.

INSERM U891, Centre de Recherche en Cancérologie de Marseille, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.10.8.15368DOI Listing
April 2011

Treatment of acute promyelocytic leukemia for older patients.

J Natl Compr Canc Netw 2011 Mar;9(3):337-42

Division of Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins University, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593588PMC
http://dx.doi.org/10.6004/jnccn.2011.0030DOI Listing
March 2011

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.

Expert Opin Investig Drugs 2011 Feb 31;20(2):287-95. Epub 2010 Dec 31.

Institut Paoli Calmettes, Department of Haematology, 232 Boulevard Sainte Marguerite, 13009 Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2011.542750DOI Listing
February 2011

A simplified, 96-well-adapted, ATP luminescence-based motility assay.

Biotechniques 2009 Oct;47(4):871-5

Inserm, U891, TrGET, Centre de Recherche en Cancérologie de Marseille, Marseille, France, Institut Paoli-Calmettes, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2144/000113250DOI Listing
October 2009